Keyword: Boston Scientific
The two remaining U.S. manufacturers of transvaginal surgical mesh have been ordered by the FDA to halt the sale and distribution of those products.
The Federal Trade Commission is requesting additional information from Boston Scientific and BTG ahead of their proposed $4.2 billion deal.
Boston Scientific redesigned its mesh implant for relieving stress urinary incontinence in men, to make it more available to a broader population.
In January, Boston Scientific paid $90 million for a portion of Millipede's shares. Now, it's picking up the rest for $325 million.
The Theranos saga has made strong showings on our past lists of the most-read stories—but this year will be its last, as the company finally bled dry.
While the vast majority of Evaluate’s top-10 list are predicted to hold their relative rankings through 2024, Boston Scientific joins BD as the only two to move forward, displacing General Electric at spot number nine with its healthy appetite for M&A deals.
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and reap billions in additional sales in new market segments.
Boston Scientific has moved to absorb BTG for $4.2 billion in cash, acquiring a pipeline that could transform its oncology franchise.
Boston Scientific saw $2.4 billion in third-quarter sales this year, with growth led by its MedSurg division of endoscopic and pelvic health devices.
On the back of a positive head-to-head trial, the FDA approved Boston Scientific’s drug-eluting stent for peripheral artery disease.